A central presentation explores how a multimodal AI biomarker drives de-escalation of androgen deprivation therapy in prostate cancer, signaling a biology-driven approach beyond traditional NCCN guidelines.

Cross-Continental transcriptomic analysis shows MMAI scores align with similar aggressive cancer gene expression across native African, African American, and European American patients, underscoring biological consistency across populations.

Artera’s MMAI platform fuses histopathology images with clinical data to gauge cancer aggressiveness and predict therapy benefit, with FDA-cleared products and CE marks supporting regulated use in multiple markets.

Benchmarking against STAR-CAP reveals MMAI risk estimates correspond with observed metastasis and prostate cancer mortality in a real-world dataset of about 20,000 patients.

The article references multiple abstract numbers, times, and locations, reflecting a broad, international validation effort across cohorts and clinical trial data.

New data presented at the 2026 ASTRO Annual Meeting reinforce the consistency and utility of MMAI across diverse global patient populations and clinical settings.

Fairness assessment across racial and age subgroups in post-rurgery prostate cancer trials shows MMAI prognostic performance is robust with no bias detected.

GenesisCare in Australia reports ASTuTE Trial data indicating MMAI can guide short-term ADT decisions, supporting avoidance or selective use of ST-ADT as appropriate.

In the POP-RT trial, MMAI aids personalized whole-pelvis radiotherapy decisions, with Indian data showing reduced distant metastases for high-risk patients receiving full pelvis radiation.

Industry leadership remarks underscore oncology’s shift toward biology-driven, personalized treatment decisions enabled by MMAI insights.

Artera will be present at ASTRO2026 Booth 2444 for attendees to learn more about the MMAI platform.